Leerink Partnrs Has Positive Outlook of McKesson Q3 Earnings

Key Points

• Leerink Partners has increased its Q3 2026 earnings per share estimate for McKesson from $9.77 to $10.11, contributing to a full-year earnings estimate of $32.77 per share.
• Multiple analysts have raised their price targets for McKesson's stock, with UBS setting a target of $860, reflecting a strong consensus rating of "Moderate Buy".
• McKesson announced a quarterly dividend increase to $0.82 per share, marking an increase from the previous quarterly dividend of $0.71.

McKesson Corporation (NYSE:MCK - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q3 2026 earnings per share estimates for McKesson in a research report issued on Tuesday, September 23rd. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $10.11 per share for the quarter, up from their prior forecast of $9.77. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson's Q4 2026 earnings at $11.36 EPS, FY2026 earnings at $38.35 EPS, FY2027 earnings at $43.82 EPS and FY2028 earnings at $49.69 EPS.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $8.26 EPS for the quarter, missing analysts' consensus estimates of $8.33 by ($0.07). The company had revenue of $97.83 billion during the quarter, compared to analyst estimates of $95.93 billion. McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.McKesson's revenue was up 23.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $7.88 earnings per share.

Other analysts also recently issued research reports about the stock. Mizuho raised their price objective on shares of McKesson from $750.00 to $770.00 and gave the stock a "neutral" rating in a research report on Wednesday. UBS Group raised their price objective on shares of McKesson from $820.00 to $860.00 and gave the stock a "buy" rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft increased their target price on McKesson from $775.00 to $856.00 and gave the stock a "buy" rating in a report on Wednesday. Morgan Stanley boosted their price target on shares of McKesson from $810.00 to $857.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, TD Cowen raised their price objective on shares of McKesson from $830.00 to $864.00 and gave the company a "buy" rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $826.91.

McKesson Stock Up 2.6%

Shares of MCK stock opened at $760.73 on Thursday. The company has a market cap of $94.62 billion, a price-to-earnings ratio of 30.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.51. McKesson has a 52 week low of $472.29 and a 52 week high of $770.00. The firm has a 50 day moving average of $696.23 and a 200-day moving average of $697.91.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MCK. Brighton Jones LLC grew its stake in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company's stock valued at $1,438,000 after purchasing an additional 798 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of McKesson during the 4th quarter valued at $55,948,000. Mattson Financial Services LLC purchased a new position in shares of McKesson during the 4th quarter valued at $228,000. Centaurus Financial Inc. lifted its position in shares of McKesson by 259.6% during the 4th quarter. Centaurus Financial Inc. now owns 7,739 shares of the company's stock valued at $4,411,000 after buying an additional 5,587 shares during the last quarter. Finally, Lansforsakringar Fondforvaltning AB publ purchased a new position in shares of McKesson during the 4th quarter valued at $24,511,000. Institutional investors own 85.07% of the company's stock.

Insider Buying and Selling at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $663.67, for a total transaction of $218,347.43. Following the completion of the sale, the chief accounting officer owned 657 shares in the company, valued at approximately $436,031.19. This represents a 33.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Brian S. Tyler sold 11,930 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $705.63, for a total value of $8,418,165.90. Following the sale, the chief executive officer owned 4,012 shares of the company's stock, valued at $2,830,987.56. This trade represents a 74.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,560 shares of company stock valued at $30,438,602 in the last quarter. 0.08% of the stock is currently owned by corporate insiders.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.4%. This is an increase from McKesson's previous quarterly dividend of $0.71. The ex-dividend date is Tuesday, September 2nd. McKesson's dividend payout ratio is currently 13.08%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.